Most Recent
Korean drug company Samsung Bioepis has filed a lawsuit seeking to invalidate German drug company Fresenius Kadi's patent for a biosimilar of blockbuster arthritis drug Humira.
Shareholders of Xenith IP have voted to approve a hard-fought takeover proposal by Australia's largest intellectual property services firm IPH, in a deal that will create an IP services giant employing a staff of over 1,000 across the Asia Pacific.
Mylan and Cipla have reached a speedy resolution of a consumer lawsuit accusing Cipla of copying the get-up of Mylan's blockbuster cholesterol drug Lipidil.
Lawyers for Queensland businessman Clive Palmer have apologised to the court for repeated delays in the Twisted Sister music copyright case, blaming the unavailability of experts and the mining magnate's involvement in the Queensland Nickel liquidation trial for his lateness.
US tobacco giant Philip Morris has failed in its challenge before IP Australia to rival British American Tobacco's application for a trade mark to be used on its electronic cigarettes.
Rival firms Apple Inc and Swatch AG have both failed in their opposition to the other's trade mark extension application, with a delegate for the trade marks office allowing Apple's Tick Different and Swatch's Think Different to proceed to registration in Australia.
A catfight has broken out between construction equipment and workwear maker Caterpillar and sneaker giant Puma, with Caterpillar arguing Puma's 'procat' trade mark is deceptively similar to its 'cat' marks.
Mylan has launched a lawsuit against Cipla for allegedly copying the get-up of its blockbuster cholesterol drug Lipidil, after losing a bid to block Cipla and Sun Pharma from selling generic versions of the drug while it appeals a ruling invalidating several claims of its patents.
Patents at the centre of a high stakes IP dispute between tech giants Motorola and Hytera have significantly more than the necessary “scintilla of inventiveness” to be deemed valid, Motorola said on the first day of a month-long trial.
A unit of Boehringer Ingelheim has been given more time to oppose a proposed patent by rival drug maker Intervet, after the German drug company's lawyers sent an email with the wrong opposition deadline.